ArticleBlood advances2016

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

Sven de Vos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.